1
|
Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galvão LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. Correction to: International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth 2019; 19:423. [PMID: 31744466 PMCID: PMC6862798 DOI: 10.1186/s12884-019-2589-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Following publication of the original article [1], the author mentioned that two additional NIH staff were involved in the development of the protocol who did not receive recognition in the Acknowledgments section in their published article.
Collapse
Affiliation(s)
- Jill F Lebov
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC, USA.
| | - Juan F Arias
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - Angel Balmaseda
- Centro Nacional de Diagnostico y Referencia, Complejo Nacional de Salud, Managua, Nicaragua
| | - William Britt
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA
| | - José F Cordero
- Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA
| | | | - Ana Lucía Garces
- Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP), Guatemala City, Guatemala
| | - K Michael Hambidge
- Section of Nutrition, Pediatrics, University of Colorado, Aurora, CO, USA
| | - Eva Harris
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
| | - Albert Ko
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.,Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Brazil
| | - Nancy Krebs
- Section of Nutrition, Pediatrics, University of Colorado, Aurora, CO, USA
| | - Ernesto T A Marques
- School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.,Instituto Aggeu Magalhães, Department of Virology and Experimental Therapeutics, FIOCRUZ, Pernambuco, Brazil
| | | | - Elizabeth McClure
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC, USA
| | - Democrito B Miranda-Filho
- Programa de Pós-Graduação em Ciências da Saúde (PPGCS) da Universidade de Pernambuco, Microcephaly Epidemic Research Group, Recife, Brazil
| | | | | | - Theresa J Ochoa
- Instituto de Medicina Tropical Alexander von Humboldt and Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Jorge E Osorio
- Department of Pathobiological Sciences, University of Wisconsin, Madison, WI, USA
| | - Deolinda M F Scalabrin
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.,Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Brazil
| | - Stacey Schultz-Cherry
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, 38105, USA
| | - George R Seage
- Department of Epidemiology, Harvard Chan School of Public Health, Boston, MA, USA
| | - Kristen Stolka
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC, USA
| | - César Augusto Ugarte-Gil
- Instituto de Medicina Tropical Alexander von Humboldt and Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru
| | | | - Michael Welton
- Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA
| | - Ricardo Ximenes
- Departamento de Medicina Tropical da Universidade Federal de Pernambuco, Microcephaly Epidemic Research Group, Recife, Brazil
| | - Carmen Zorrilla
- Maternal-Infant Studies Center (CEMI), San Juan, Puerto Rico
| |
Collapse
|
2
|
Lebov JF, Arias JF, Balmaseda A, Britt W, Cordero JF, Galvão LA, Garces AL, Hambidge KM, Harris E, Ko A, Krebs N, Marques ETA, Martinez AM, McClure E, Miranda-Filho DB, Moreira MEL, Mussi-Pinhata MM, Ochoa TJ, Osorio JE, Scalabrin DMF, Schultz-Cherry S, Seage GR, Stolka K, Ugarte-Gil CA, Vega CMV, Welton M, Ximenes R, Zorrilla C. International prospective observational cohort study of Zika in infants and pregnancy (ZIP study): study protocol. BMC Pregnancy Childbirth 2019; 19:282. [PMID: 31391005 PMCID: PMC6686399 DOI: 10.1186/s12884-019-2430-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 07/26/2019] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Until recently, Zika virus (ZIKV) infections were considered mild and self-limiting. Since 2015, they have been associated with an increase in microcephaly and other birth defects in newborns. While this association has been observed in case reports and epidemiological studies, the nature and extent of the relationship between ZIKV and adverse pregnancy and pediatric health outcomes is not well understood. With the unique opportunity to prospectively explore the full spectrum of issues related to ZIKV exposure during pregnancy, we undertook a multi-country, prospective cohort study to evaluate the association between ZIKV and pregnancy, neonatal, and infant outcomes. METHODS At research sites in ZIKV endemic regions of Brazil (4 sites), Colombia, Guatemala, Nicaragua, Puerto Rico (2 sites), and Peru, up to 10,000 pregnant women will be recruited and consented in the first and early second trimesters of pregnancy and then followed through delivery up to 6 weeks post-partum; their infants will be followed until at least 1 year of age. Pregnant women with symptomatic ZIKV infection confirmed by presence of ZIKV RNA and/or IgM for ZIKV will also be enrolled, regardless of gestational age. Participants will be tested monthly for ZIKV infection; additional demographic, physical, laboratory and environmental data will be collected to assess the potential interaction of these variables with ZIKV infection. Delivery outcomes and detailed infant assessments, including physical and neurological outcomes, will be obtained. DISCUSSION With the emergence of ZIKV in the Americas and its association with adverse pregnancy outcomes in this region, a much better understanding of the spectrum of clinical outcomes associated with exposure to ZIKV during pregnancy is needed. This cohort study will provide information about maternal, fetal, and infant outcomes related to ZIKV infection, including congenital ZIKV syndrome, and manifestations that are not detectable at birth but may appear during the first year of life. In addition, the flexibility of the study design has provided an opportunity to modify study parameters in real time to provide rigorous research data to answer the most critical questions about the impact of congenital ZIKV exposure. TRIAL REGISTRATION NCT02856984 . Registered August 5, 2016. Retrospectively registered.
Collapse
Affiliation(s)
- Jill F. Lebov
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC USA
| | - Juan F. Arias
- Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN 38105 USA
| | - Angel Balmaseda
- Centro Nacional de Diagnostico y Referencia, Complejo Nacional de Salud, Managua, Nicaragua
| | - William Britt
- Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL USA
| | - José F. Cordero
- Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA USA
| | | | - Ana Lucía Garces
- Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP), Guatemala City, Guatemala
| | | | - Eva Harris
- Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA USA
| | - Albert Ko
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT USA
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Brazil
| | - Nancy Krebs
- Section of Nutrition, Pediatrics, University of Colorado, Aurora, CO USA
| | - Ernesto T. A. Marques
- School of Public Health, University of Pittsburgh, Pittsburgh, PA USA
- Instituto Aggeu Magalhães, Department of Virology and Experimental Therapeutics, FIOCRUZ, Pernambuco, Brazil
| | | | - Elizabeth McClure
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC USA
| | - Democrito B. Miranda-Filho
- Programa de Pós-Graduação em Ciências da Saúde (PPGCS) da Universidade de Pernambuco, Microcephaly Epidemic Research Group, Recife, Brazil
| | | | | | - Theresa J. Ochoa
- Instituto de Medicina Tropical Alexander von Humboldt and Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru
| | - Jorge E. Osorio
- Department of Pathobiological Sciences, University of Wisconsin, Madison, WI USA
| | - Deolinda M. F. Scalabrin
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT USA
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Brazil
| | - Stacey Schultz-Cherry
- Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN 38105 USA
| | - George R. Seage
- Department of Epidemiology, Harvard Chan School of Public Health, Boston, MA USA
| | - Kristen Stolka
- Social, Statistical and Environmental Sciences, RTI International, Durham, NC USA
| | - César Augusto Ugarte-Gil
- Instituto de Medicina Tropical Alexander von Humboldt and Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru
| | | | - Michael Welton
- Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA USA
| | - Ricardo Ximenes
- Departamento de Medicina Tropical da Universidade Federal de Pernambuco, Microcephaly Epidemic Research Group, Recife, Brazil
| | - Carmen Zorrilla
- Maternal-Infant Studies Center (CEMI), San Juan, Puerto Rico
| |
Collapse
|
3
|
Foiles AM, Kerling EH, Wick JA, Scalabrin DMF, Colombo J, Carlson SE. Formula with long-chain polyunsaturated fatty acids reduces incidence of allergy in early childhood. Pediatr Allergy Immunol 2016; 27:156-61. [PMID: 26613373 PMCID: PMC5207026 DOI: 10.1111/pai.12515] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/22/2015] [Indexed: 01/01/2023]
Abstract
BACKGROUND Allergy has sharply increased in affluent Western countries in the last 30 years. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) may protect the immune system against development of allergy. METHODS We prospectively categorized illnesses by body system in a subset of 91 children from the Kansas City cohort of the DIAMOND (DHA Intake and Measurement of Neural Development) study who had yearly medical records through 4 years of age. As infants, they were fed either a control formula without LCPUFA (n = 19) or one of three formulas with LCPUFA from docosahexaenoic acid (DHA) and arachidonic acid (ARA) (n = 72). RESULTS Allergic illnesses in the first year were lower in the combined LCPUFA group compared to the control. LCPUFAs significantly delayed time to first allergic illness (p = 0.04) and skin allergic illness (p = 0.03) and resulted in a trend to reduced wheeze/asthma (p = 0.1). If the mother had no allergies, LCPUFAs reduced the risk of any allergic diseases (HR = 0.24, 95% CI = 0.1, 0.56, p = 0.0.001) and skin allergic diseases (HR = 0.35, 95% CI = 0.13, 0.93, p = 0.04). In contrast, if the mother had allergies, LCPUFAs reduced wheezing/asthma (HR = 0.26, 95% CI = 0.07, 0.9, p = 0.02). CONCLUSIONS LCPUFA supplementation during infancy reduced the risk of skin and respiratory allergic diseases in childhood with effects influenced by maternal allergies.
Collapse
Affiliation(s)
| | | | - Jo A Wick
- University of Kansas Medical Center, Kansas City, KS, USA
| | | | | | | |
Collapse
|
4
|
Pontes MV, Ribeiro TCM, Ribeiro H, de Mattos AP, Almeida IR, Leal VM, Cabral GN, Stolz S, Zhuang W, Scalabrin DMF. Cow's milk-based beverage consumption in 1- to 4-year-olds and allergic manifestations: an RCT. Nutr J 2016; 15:19. [PMID: 26920136 PMCID: PMC4769487 DOI: 10.1186/s12937-016-0138-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Accepted: 02/18/2016] [Indexed: 12/31/2022] Open
Abstract
Background Nutrients such as docosahexaenoic acid (DHA), prebiotics and β-glucan have been associated with reduced incidence of respiratory illnesses and allergic manifestations (AM). Our objective was to assess if consumption of a cow’s milk-based beverage with these and other nutrients supports respiratory, gastrointestinal, and skin health in otherwise well-nourished, healthy children. Methods In this double-blind, randomized, controlled trial, healthy children (1–4 years of age) from two daycare centers in Brazil were fed three servings/day of a cow’s milk-based beverage (CMBB; n = 125) containing DHA, the prebiotics polydextrose (PDX) and galactooligosaccharides (GOS), β-glucan, and other key nutrients, or a control cow’s milk-based beverage (control; n = 131) for up to 28 weeks. Occurrence of respiratory infections, diarrheal disease and AM was assessed by study pediatricians and the number of episodes were analyzed with the Cochran-Mantel-Haenszel test and the Andersen-Gill model. Results The CMBB group had fewer episodes of AM, which included allergic rhinitis or conjunctivitis, wheezing, allergic cough, eczema and urticaria, compared to the control group (p = 0.021). The hazard ratio for increased number of episodes of AM was lower in the CMBB group compared to control (HR, 0.64; 95 % CI 0.47–0.89; p = 0.007). There was no difference in the incidence of respiratory infections and diarrheal disease between groups. Conclusion A cow’s milk-based beverage containing DHA, PDX/GOS, and yeast β-glucan, and supplemented with micronutrients, including zinc, vitamin A and iron, when consumed 3 times/day for 28 weeks by healthy 1- to 4-year-old children was associated with fewer episodes of allergic manifestations in the skin and the respiratory tract. Trial registration registration number: NCT01431469
Collapse
Affiliation(s)
- M V Pontes
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - T C M Ribeiro
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - H Ribeiro
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - A P de Mattos
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - I R Almeida
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - V M Leal
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - G N Cabral
- Federal University of Bahia, Salvador, Bahia, Brazil.
| | - S Stolz
- Mead Johnson Pediatric Nutrition Institute, Evansville, IN, USA.
| | - W Zhuang
- Mead Johnson Pediatric Nutrition Institute, Evansville, IN, USA.
| | - D M F Scalabrin
- Mead Johnson Pediatric Nutrition Institute, Evansville, IN, USA.
| |
Collapse
|
5
|
Muraro A, Hoekstra MO, Meijer Y, Lifschitz C, Wampler JL, Harris C, Scalabrin DMF. Extensively hydrolysed casein formula supplemented with Lactobacillus rhamnosus GG maintains hypoallergenic status: randomised double-blind, placebo-controlled crossover trial. BMJ Open 2012; 2:e000637. [PMID: 22396223 PMCID: PMC3298831 DOI: 10.1136/bmjopen-2011-000637] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVE To evaluate the hypoallergenicity of an extensively hydrolysed (EH) casein formula supplemented with Lactobacillus rhamnosus GG (LGG). DESIGN A prospective, randomised, double-blind, placebo-controlled crossover trial. SETTING Two study sites in Italy and The Netherlands. STUDY PARTICIPANTS Children with documented cow's milk allergy were eligible for inclusion in this trial. INTERVENTIONS After a 7-day period of strict avoidance of cow's milk protein and other suspected food allergens, participants were tested with an EH casein formula with demonstrated hypoallergenicity (control, EHF) and a formula of the same composition with LGG added at 10(8) colony-forming units per gram powder (EHF-LGG) in randomised order in a double-blind placebo-controlled food challenge (DBPCFC). After absence of adverse reactions in the DBPCFC, an open challenge was performed with EHF-LGG, followed by a 7-day home feeding period with the same formula. MAIN OUTCOME MEASURE Clinical assessment of any adverse reactions to ingestion of study formulae during the DBPCFC. RESULTS For all participants with confirmed cow's milk allergy (n=31), the DBPCFC and open challenge were classified as negative. CONCLUSION The EH casein formula supplemented with LGG is hypoallergenic and can be recommended for infants and children allergic to cow's milk who require an alternative to formulae containing intact cow's milk protein. TRIAL REGISTRATION NUMBER http://ClinicalTrials.gov Identifier: NCT01181297.
Collapse
Affiliation(s)
- Antonella Muraro
- The Food Allergy Referral Centre, Department of Pediatrics, Veneto Region, Università degli Studi di Padova, Padova, Italy
| | - Maarten O Hoekstra
- Department of Paediatrics, University Medical Centre St Radboud, Nijmegen, The Netherlands
| | - Yolanda Meijer
- Wilhelmina Childrens' Hospital, University Medical Centre, Utrecht, The Netherlands
| | - Carlos Lifschitz
- Departamento de Pediatria, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Jennifer L Wampler
- Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana, USA
| | - Cheryl Harris
- Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana, USA
| | - Deolinda M F Scalabrin
- Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, Indiana, USA
| |
Collapse
|
6
|
Burks W, Jones SM, Berseth CL, Harris C, Sampson HA, Scalabrin DMF. Hypoallergenicity and effects on growth and tolerance of a new amino acid-based formula with docosahexaenoic acid and arachidonic acid. J Pediatr 2008; 153:266-71. [PMID: 18534230 DOI: 10.1016/j.jpeds.2008.02.043] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2007] [Revised: 12/12/2007] [Accepted: 02/21/2008] [Indexed: 10/22/2022]
Abstract
OBJECTIVE In study 1, to compare the effect on growth in healthy infants of a new amino acid-based formula (AAF) and a control extensively hydrolyzed formula (EHF), with both docosahexaenoic acid (DHA) and arachidonic acid (ARA) at levels similar to those in human milk worldwide. In study 2, to evaluate the hypoallergenicity of this new AAF in infants and children with confirmed cow's milk allergy (CMA). STUDY DESIGN In study 1, a total of 165 healthy, full-term, formula-fed infants randomly received the new AAF or control formula. Anthropometric measurements, tolerance, and adverse events were recorded throughout the study. Plasma amino acid profiles were evaluated in a subset of the infants. In study 2, the hypoallergenicity of the new AAF was evaluated in 32 infants and children using a double-blind, placebo-controlled food challenge; an open challenge; and a 7-day feeding. RESULTS In study 1, overall growth, tolerance, and safety outcomes were similar in both groups. In study 2, 29 of the 32 subjects completed both challenges; no allergic reaction was seen in any of the 32 subjects. CONCLUSIONS The new AAF with DHA and ARA at levels similar to those in human milk worldwide is hypoallergenic. It also is safe and supports growth in healthy, term infants.
Collapse
Affiliation(s)
- Wesley Burks
- Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
| | | | | | | | | | | |
Collapse
|